Search Within

Alison Moskowitz

Formats
  1. Meeting Abstract (196)
  2. Journal Article (126)
  3. Review (13)
  4. Research Letter (12)
  5. Editorial (5)
  6. Guidelines (4)
  7. Correspondence (2)
  8. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (359)
  2. Department of Medicine (359)
  3. Hematologic Malignancies, Division of (359)
  4. Lymphoma (359)
  5. Population Sciences Research Program (235)
  6. Survivorship Research (149)

More Groups

People
  1. Steven Horwitz (234)
  2. Andrew Zelenetz (130)
  3. Paul Hamlin (119)
  4. Ariela Noy (118)
  5. Anita Kumar (106)
  6. Maria Palomba (103)

More People

Years
  1. 2025 (11)
  2. 2024 (37)
  3. 2023 (37)
  4. 2022 (20)
  5. 2021 (36)
  6. 2020 (30)

More Years

Publications
  1. Blood (150)
  2. Hematological Oncology (23)
  3. Journal of Clinical Oncology (22)
  4. Blood Advances (15)
  5. Leukemia and Lymphoma (15)
  6. Journal of the American Academy of Dermatology (14)

More Publications

Publishers
  1. American Society of Hematology (168)
  2. Wiley Blackwell (31)
  3. American Society of Clinical Oncology (25)
  4. Elsevier Inc. (22)
  5. Taylor & Francis Group (16)
  6. Mosby Elsevier (14)

More Publishers

Results (359)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
    Journal Article

    Ghione, P.; Bantilan, K. S.; Joffe, E.; Palomba, M. L.; Noy, A.; Caron, P.; Hamlin, P.; Kumar, A.; Matasar, M.; Owens, C.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab
    Meeting Abstract

    Steiner, R.; Bock, A. M.; Herrera, A. F.; Zulfa, O.; Hoffmann, M.; Ibrahimi, S.; Galanina, N.; Lee, H. J.; Green, M.; Lin, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Investigating the novel combination of the innate cell engager (ICE®) acimtamig with off-the-shelf allogeneic natural killer cells AlloNK® in relapsed or refractory classical Hodgkin lymphoma (R/R cHL): Initial results of the phase 2 Luminice-203
    Meeting Abstract

    Maakaron, J.; Modi, D.; Mei, M. T.; Feldman, T.; Shah, G. L.; Mehta, A. N.; Sauter, C. S.; Khanal, R.; Barta, S. K.; Emig, M.; more...
    Blood (2024)

    Fulltext@MSK | Save